Microbot Medical Secures Peer-Review Validation for LIBERTY Robotic System
Event summary
- Microbot Medical published its ACCESS PVI Pivotal Study in the Journal of Vascular and Interventional Radiology on March 24, 2026.
- The study, led by Dr. Francois Cornelis, underwent rigorous peer review, validating the LIBERTY system's efficacy for peripheral endovascular procedures.
- LIBERTY received FDA clearance in September 2025 and is set for full market release at the SIR conference in April 2026.
- The system is the only FDA-cleared, single-use, remotely operated robotic solution for peripheral endovascular procedures.
The big picture
Microbot Medical's peer-reviewed publication solidifies LIBERTY's position in the endovascular robotics space, a sector increasingly driven by precision and minimally invasive technologies. The FDA clearance and upcoming full market release position Microbot to compete with established players in robotic-assisted surgery, leveraging its unique single-use design to reduce procedural risks and costs.
What we're watching
- Clinical Adoption
- How the peer-reviewed validation will accelerate LIBERTY's adoption in peripheral vascular interventions.
- Market Expansion
- Whether Microbot can sustain momentum post-FDA clearance and scale commercial adoption.
- Competitive Positioning
- The pace at which Microbot can differentiate LIBERTY in a growing robotic-assisted surgery market.
Related topics